Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25775428
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 BMJ+Clin+Evid
2015 ; 2015
(ä): ä Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Candidiasis (vulvovaginal)
#MMPMID25775428
Martin Lopez JE
BMJ Clin Evid
2015[Mar]; 2015
(ä): ä PMID25775428
show ga
INTRODUCTION: Vulvovaginal candidiasis is estimated to be the second most common
cause of vaginitis after bacterial vaginosis. Candida albicans accounts for 85%
to 90% of cases. METHODS AND OUTCOMES: We conducted a systematic review and aimed
to answer the following clinical questions: What are the effects of drug
treatments for acute vulvovaginal candidiasis in non-pregnant symptomatic women?
What are the effects of alternative or complementary treatments for acute
vulvovaginal candidiasis in non-pregnant symptomatic women? What are the effects
of treating asymptomatic non-pregnant women with a positive swab for candidiasis?
We searched: Medline, Embase, The Cochrane Library, and other important databases
up to October 2013 (Clinical Evidence reviews are updated periodically; please
check our website for the most up-to-date version of this review). We included
harms alerts from relevant organisations such as the US Food and Drug
Administration (FDA) and the UK Medicines and Healthcare products Regulatory
Agency (MHRA). RESULTS: We found 23 studies that met our inclusion criteria. We
performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review, we present information relating to the
effectiveness and safety of the following interventions: alternative or
complementary treatments; douching; drug treatments; garlic; intravaginal
preparations (nystatin, imidazoles, tea tree oil); oral fluconazole; oral
itraconazole; and yoghurt containing Lactobacillus acidophilus (oral or
intravaginal).